Chandrasekaran, Ravichandran http://orcid.org/0000-0002-9221-1264
Dávoli, Mauro http://orcid.org/0000-0003-0584-1901
Muda, Zulaiha
Pérez-Lozano, Uendy http://orcid.org/0000-0003-2425-2037
Salhi, Naouel
Saxena, Nakul http://orcid.org/0000-0002-6717-4975
Shen, Ming-Ching http://orcid.org/0000-0001-7789-2148
Song, HyeRyoung Haylee
Sosothikul, Darintr http://orcid.org/0000-0003-1097-3482
Soto-Arellano, Veronica Soledad http://orcid.org/0000-0002-0015-5219
Solev, Igor
Funding for this research was provided by:
Takeda Pharmaceuticals International AG – Singapore Branch
Article History
Received: 1 December 2022
Accepted: 2 October 2023
First Online: 10 November 2023
Declarations
:
: All interviewees gave informed consent to take part in interviews. All methods were carried out in accordance with relevant guidelines and regulations. There was no requirement for review board sign offs for the interviews.
: Not applicable.
: Competing interests: RC, MD, ZM, UP-L, Nao.S, MCS, DS, and VS received interview honoraria fees from Takeda. Nak.S and IS were employees of Takeda Pharmaceuticals International AG Singapore Branch at the time of analysis. HHS is a current employee of Takeda Pharmaceuticals International AG Singapore Branch. Nak.S and HHS report stock options held in Takeda Pharmaceutical Company Ltd.